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Clinical significance 
• Cardiovascular events were the most common cause of death (54% of cases) in a large study 
of hospitalized patients with atrial fibrillation.  
• Fatal stroke or fatal bleeding each accounted for 7% of all deaths. 
• The strongest predictors of overall death were permanent atrial fibrillation, heart failure 
(whether with decreased or with preserved ejection fraction), previous bleeding and renal 
failure. 
• Oral anticoagulant use was independently associated with a lower risk of all-cause mortality, 
cardiovascular mortality, and non-cardiovascular mortality. 
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ABSTRACT 
Background: Atrial fibrillation is associated with a higher mortality, but causes of death of atrial 
fibrillation patients and their specific predictors have been less well defined. We aimed to 
identify the causes of death among atrial fibrillation patients and secondly, clinical predictors for 
the different modes of deaths. 
Methods: Patients diagnosed with atrial fibrillation in a four-hospital institution between 2000 
and 2010 were identified. During a follow-up of 929±1082 days (median 456, interquartile 10-
1584), 1253 deaths were recorded (yearly rate 5.5%).  
Results: Cardiovascular deaths accounted for 54% and non-cardiovascular in 43%. The three 
main causes of death were heart failure (29%), infection (18%) and cancer (12%). Fatal stroke or 
fatal bleeding each accounted for 7% of all deaths. On multivariate analysis, the strongest 
predictors of death were permanent atrial fibrillation, heart failure (whether with decreased or 
with preserved ejection fraction), previous bleeding and renal failure, which were independently 
associated with an increase in the risk of all cause mortality (35%, 78%, 42% and 79% 
respectively), cardiovascular mortality (43%, 129%, 46% and 93%) and non-cardiovascular 
mortality (21%, 45%, 40% and 50%). Oral anticoagulant use was independently associated with a 
lower risk of all-cause mortality (hazard ratio[HR] 0.62, 95% confidence interval [CI] 0.54-0.71, 
p<0.0001), cardiovascular mortality (HR 0.60, 95%CI 0.49-0.72, p<0.0001), and non-
cardiovascular mortality (HR 0.60, 95%CI 0.49-0.74, p<0.0001).  
Conclusions: The majority of deaths were related to a cardiovascular origin and heart failure was 
the most common cause of death in atrial fibrillation patients. Despite the high risk of stroke 
associated with atrial fibrillation, only 7% died from stroke. Optimization of management of any 
underlying heart disease and associated comorbidities should be a relevant therapeutic target to 
reduce total mortality in atrial fibrillation patients. 
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INTRODUCTION 
 
Atrial fibrillation is the most common sustained arrhythmia and significantly increases mortality 
and morbidity, and impairs quality of life. Strategies to reduce overall atrial fibrillation-related 
mortality are focused on the prevention of thromboembolism. Indeed, oral anticoagulation with 
the Vitamin K antagonists (VKA, eg. warfarin) significantly reduce stroke and systemic 
embolism by 64% compared to placebo or control, although all-cause mortality is also 
significantly reduced by 26% 1. The development of non vitamin-K oral anticoagulants (NOACs) 
which are simpler to use, and at least as effective and safe as vitamin K antagonist (VKA) may 
provide additional reductions in morbidity and mortality in this population 2. 
 
However, patients with atrial fibrillation often have several cardiovascular risk factors, structural 
heart disease, and comorbidities, all of which can increase mortality 3–7. Thus, besides the risk of 
fatal hemorrhage conferred by anti-thrombotic therapy, the causes of death (and their predictors) 
in patients with atrial fibrillation are less well defined. Identifying causes of death and their 
predictors in patients with atrial fibrillation is crucial in enabling the development of effective 
targeted interventions and reducing overall mortality in this population. The objective of this 
study was to identify the causes of death among atrial fibrillation patients and secondly, clinical 
predictors for the different modes of deaths. 
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METHODS 
 
We included all patients with a diagnosis of atrial fibrillation seen in the cardiology department in 
our institution between January 2000 and December 20108. Atrial fibrillation was defined on the 
electrocardiogram by the replacement of consistent P waves by rapid oscillations or fibrillatory 
waves that vary in amplitude, shape, and timing, associated with an irregular, often rapid 
ventricular response. Patients’ characteristics were obtained from the records of our institution’s 
computerized codification system for each patient. Extensive information was collected on date 
of admission, discharge, diagnosis, clinical presentation, comorbidities, medication and 
subsequent hospitalization or outpatient visit. Patients entered into the study on their first 
cardiology encounter during the study period with atrial fibrillation. For each patient, the 
thromboembolic risk was estimated at the time of entry into the study using the CHA2DS2-VASc 
(acronym for Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes, 
Stroke/TIA/thromboembolism (doubled), Vascular disease (prior myocardial infarction, 
peripheral artery disease, or aortic plaque), Age 65-74 years, Sex category [female]) score and the 
haemorrhagic risk using the HAS-BLED (acronym for hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol 
concomitantly) bleeding risk score. The SAMe TT2R2 (acronym for Sex, Age <60 years; Medical 
history [at least 2 of the following: hypertension, diabetes, coronary artery disease/myocardial 
infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary 
disease, hepatic or renal disease]; Treatment [interacting drugs, eg, amiodarone for rhythm 
control] [all 1 point]; current Tobacco use (2 points) and Race [non-Caucasian; 2 points]) score 
was used to predict poor INR control in patients with atrial fibrillation treated with VKA9–13. 
None of the patients were treated with NOAC during this study period.   
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During follow-up, deaths from all causes and events of interest were recorded whenever they 
occurred in our institution, which includes a total of 4 hospitals covering all medical and surgical 
specialties. Our hospital covers an area of 4000 km2, and a population of 400.000 inhabitants and 
is the only public institution in the area. In addition, mortality data were obtained using a search 
tool from a dedicated website for the Région Centre 
(http://nrco.lanouvellerepublique.fr/dossiers/necro/index.php). The causes of death occurring in 
the University Hospital of Tours were collected through computerized hospitalization reports. For 
those that occurred outside our institution, they were collected by telephone from treating 
physicians, retirement homes or families. Mode of death was adjudicated based on medical 
reports and autopsy reports or death certificates when available. This information was reviewed 
by 2 investigators and causes of death were adjudicated after consideration of all the available 
information, and according to the following prespecified groups: cardiovascular, 
noncardiovascular, as well as unknown when the quality of the information could not allow the 
investigators to appropriately identify cause of death.  
 
The study was approved by the institutional review board of the Pole Coeur Thorax Vaisseaux 
from the Trousseau University Hospital, on December 7, 2010 and registered as a clinical audit. 
Ethical review was therefore not required. Patient consent was not sought. The study was 
conducted retrospectively, patients were not involved in its conduct, and there was no impact on 
their care. 
 
Statistical analysis 
Patient characteristics are reported as percentages and the mean ± standard deviation (SD). 
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Comparisons between groups were made using chi-square tests for comparing categorical 
variables and the Student t test or non-parametric Kruskal Wallis test were appropriate for 
continuous variables. Cumulative incidence rates of events were calculated for all patients by 
subgroups of interest. A Cox proportional hazards regression model was used to calculate the 
hazard ratio (HR) of predictive factors and their 95% confidence interval (CI) for the incidence of 
events. The proportional hazard assumption was checked by plotting the log-log Kaplan Meier 
curves. A p-value < 0.05 was considered statistically significant. Statistical analysis was carried 
out with the Statview 5.0 software (Abacus Concepts, Berkley, CA, USA).  
 
RESULTS 
 
A total of 8,962 patients with atrial fibrillation were included between January 2000 and 
December 2010. During a follow-up of 929 ± 1082 days (median 456, interquartile 10-1584), 
1294 patients died (14%, yearly rate of death 5.5%) and 97% of causes of death were identified. 
 
Patient characteristics 
Patients who died during follow-up were older, were more frequently with permanent atrial 
fibrillation and had higher CHA2DS2-VASc score, HASBLED score and SAMeTT2R2 score 
(Table 1).. Among patients with heart failure, 51% had ischemic etiology and among those with 
left ventricular ejection fraction measured in the 6 previous months with either echocardiography 
or angioscintigraphy, there were 34% with reduced left ventricular ejection fraction <40% and  
24% with ejection fraction 40-49%. In patients with heart failure, 52% were treated with beta-
blockers (59% in those with ejection fraction <40%, 57% in those with ejection fraction 40-49% 
and 43% in those with ejection fraction ≥50%. Among patients who died during the follow-up, 
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there was a higher prevalence of patients with various cardiovascular comorbidities, as well as 
alcohol abuse and active smoking. The proportion of patients with coronary artery disease, heart 
failure (whether with decreased or preserved ejection fraction) and those with a left ventricular 
ejection fraction <40% was higher among the patients dead at the end of follow-up Non-use of 
antithrombotic therapy was higher, and the proportion of patients on VKA was lower, among 
those who died during follow-up. The proportion of patients on beta-blockers was higher among 
the patients alive at the end of follow-up.  
 
Causes of death and impact of prescription of VKA 
Among the 1,294 causes of death identified, 699 (54%) were cardiovascular and 552 (43%) non-
cardiovascular. Heart failure was the primary cause of cardiovascular deaths (29.2%) whereas 
infection (17.6%) was the primary cause of non-cardiovascular deaths (Figure 1, Table 2). 
 
After adjustment for age, sex, characteristics of atrial fibrillation (permanent or non-permanent), 
comorbidities and treatments, the prescription of VKA was independently associated with a lower 
overall mortality, cardiovascular mortality and non-cardiovascular mortality (risk reduction of 
38%, 40% and 40%) (Table 3). Among cardiovascular deaths, prescription of VKA was 
associated with a non-significantly lower risk of fatal stroke in our cohort. Central nervous 
system fatal hemorrhage was not independently linked with prescription of VKA. VKA use was 
also associated with a lower risk of vascular events such as fatal pulmonary embolism or fatal 
aortic syndrome.  
 
Among non-cardiovascular death, prescription of VKA was independently associated with a 
higher risk of fatal trauma (245%). This higher risk was not significant for deaths from cerebral 
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trauma but was significant for other trauma-related deaths (Table 3). 
 
Independent predictors of the main causes of death 
Besides age and male gender, the presence of permanent atrial fibrillation, heart failure (whether 
with systolic dysfunction or with preserved ejection fraction, and with ischemic or non-ischemic 
etiology), previous major bleeding and renal failure were independently associated with an 
increase in the risk of overall mortality (35%, 78%, 42% and 79% respectively), cardiovascular 
mortality (43%, 129%, 46% and 93%) and non-cardiovascular mortality (21%, 45%, 40% and 
50%) (Table 4).  
 
Death due to heart failure was independently associated with permanent atrial fibrillation, 
coronary artery disease, previous heart failure (whether with decreased or with preserved ejection 
fraction), previous acute coronary syndrome, renal failure or left bundle branch block. Of note, 
use of beta-blockers was associated with a 22% decrease in the risk of death related to heart 
failure. Death due to sudden cardiac death was independently associated with older age, history 
of heart failure (whether with decreased or with preserved ejection fraction), and renal failure 
(Table 5).  
 
There were more permanent atrial fibrillation patients who died due to a fatal stroke, and as 
expected, age and CHA2DS2-VASc scores were significant predictors of fatal stroke. For fatal 
bleeding, HASBLED score, age and renal failure were predictors on the unadjusted analysis, but 
only age was significant predictor for more fatal bleeds on adjustment. Patients with a 
prescription of VKA had lower risk of death from fatal bleeding (Table 6). 
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DISCUSSION 
 
In our cohort, the three main causes of death were heart failure (29%), infections (18%) and 
cancer (12%), whilst stroke and hemorrhagic-related deaths each only contributed for 
approximately 7% of causes of death. Second, the presence of permanent atrial fibrillation, heart 
failure (whether with decreased or with preserved ejection fraction), previous bleeding and renal 
failure were all independently associated with an increase in the risk of all cause mortality, 
cardiovascular mortality and non-cardiovascular mortality. Third, oral anticoagulant use was 
independently associated with a lower risk of mortality. 
 
Our work is the first to detail the causes of mortality and identified independent predictors of the 
main causes of death in a large population of unselected and well characterized patients with 
atrial fibrillation.  
The identification of these predictors for the specific mode of death may help to develop effective 
targeted interventions in order to reduce overall atrial fibrillation-related mortality. 
 
VKA use was independently associated with a decrease in overall mortality during follow-up, as 
was previously suggested for patients seen in randomized trials 1. While 24% of patients who 
died did not receive thromboprophylaxis in our cohort, the distribution of causes of death in our 
cohort was different (with lower rates of cardiovascular deaths and fatal strokes) than that seen in 
the RE-LY analysis 14. The latter was a selected clinical trial population in which all patients 
were receiving anticoagulant therapy.  
 
Our work suggests that anticoagulation is perhaps not the only consideration amongst strategies 
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for the reduction of atrial fibrillation-related mortality, and we should also target comorbidities 
associated with atrial fibrillation. Indeed, we found that heart failure (whether with decreased or 
with preserved ejection fraction) increased risk of overall mortality (78%), cardiovascular 
mortality (129%), non-cardiovascular mortality (45%), heart failure-related mortality (178%) and 
sudden cardiac death (222%). These data are consistent with the RE-LY trial analysis, although a 
lower annual rate of death (3.8%) was seen 14. Similarly, in the recent observational XANTUS 
study of atrial fibrillation patients treated with rivaroxaban, death occurred in 118 patients (yearly 
rate 1.9%) within the study treatment period, with the adjudicated cause of death due primarily to 
cardiovascular causes, mainly heart failure, followed by cancer 15. Our findings clearly reflect the 
less selected ‘real world’ nature of our atrial fibrillation patients, given the annual rate of death 
was 5.5%.  
 
In our cohort, only 52% of atrial fibrillation patients with heart failure (with decreased or with 
preserved ejection fraction) were treated with beta-blockers as in other studies 16. We found that 
patients who died during follow-up had a significantly lower rate of prescription of beta-blockers. 
Of note, beta-blocker use was independently associated with a decrease of 22% in the risk of 
heart failure- related mortality while there was no association with a lower risk of sudden death in 
our patients. This is consistent with another large study from the Danish nationwide cohort study 
17
. However, a recent individual patient metaanalysis of trial data suggests that the effect of beta-
blockers on outcome in HF patients with reduced systolic LVEF who have atrial fibrillation may 
be less than in those who have sinus rhythm 18. Although the subject is currently debated, 
increasing the rate of patients with atrial fibrillation and heart failure treated according to 
guidelines remains crucial, particularly for those with systolic heart failure, in order to decrease 
mortality in contemporary populations 19. Patients not using beta-blockers may also have 
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hypotension or low rate permanent atrial fibrillation, selecting a population with a worse 
prognosis. 
 
Renal failure increases the morbidity, overall mortality and cardiovascular mortality in 
populations that it affects 20–23. Although deaths from renal failure-related death represented only 
1.55% of all causes of death, renal failure also appeared to be a strongly associated with mortality 
amongst patients with atrial fibrillation. A similar finding was recently reported for atrial 
fibrillation patients dying in French hospitals, although there was no information on medication 
use 24. After adjustment of potential confounding parameters, renal failure was independently 
associated with a higher risk of overall mortality (21%, which is consistent with the Danish 
Registry data on 132,372 patients with atrial fibrillation 25), as well as cardiovascular mortality 
(93 %), non-cardiovascular mortality (50%), heart failure-related death (124%) and sudden 
cardiac death (145%). The result on total mortality was also consistent with the Danish Registry 
data on 132,372 patients with atrial fibrillation, although this did not analyze the mode of death 
25
. By contrast, renal failure was not an independent predictor of occurrence of a fatal stroke or 
fatal hemorrhage on multivariate analysis.  
 
Permanent atrial fibrillation was independently associated with an increased risk of overall 
mortality, cardiovascular mortality, non-cardiovascular mortality, heart failure-related death and 
fatal stroke, as previously reported for some of this findings 26–30. However, our analysis is to our 
knowledge one of the first to report how permanent atrial fibrillation might be related to the mode 
of death. Nonetheless, a strategy of using drugs for rhythm control has not been found to be 
superior to rate control 31, and the impact of atrial fibrillation ablation catheter techniques on 
mortality is currently unknown. Our findings for permanent atrial fibrillation show association 
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and not causation. Rather than focus on rhythm control, our study suggests that the optimizing 
treatment of underlying heart disease which commonly complicates atrial fibrillation, or cardiac 
remodeling induced by atrial fibrillation, should be an important management consideration. 
 
Study limitations 
Our study was observational and not a randomized study, but this gives it the benefit of being a 
less biased reflection of events in a population of consecutive patients with atrial fibrillation. One 
needs to interpret associations with caution, and not attempt to infer causation. Permanent atrial 
fibrillation could be an expression of patients comorbidities with a worse overall state including a 
worse prognosis. It is plausible that the patients on VKA were younger and healthier, hence 
tolerated VKA and they may have had lower mortality rate because they were healthier. This 
possibly explains that patients with VKA had lower risk of death from fatal bleeding whilst one 
would not expect anticoagulation to actually reduce risk of bleeding. Quality of anticoagulation 
with time in therapeutic range was not available. Studies with a long-term follow-up as this one 
are often at risk of changes in treatment during the follow-up, which is impossible to make 
adjustments for in the multivariable analysis. It was also a monocentric study and our results 
should be interpreted with caution regarding the general population. Patients in different disease 
states were included (those with new-onset atrial fibrillation and those with multiple years of 
atrial fibrillation history) and this may hamper the interpretation of predictors. We did not 
differentiate between progressive heart failure and immediately lethal heart failure (myocardial 
infarction complicated by fatal cardiogenic shock for example). Finally, we did not have a control 
group (patients without atrial fibrillation) that would have allowed us to compare the distribution 
and predictors of each of the specific causes of mortality in patients with atrial fibrillation. The 
rate of cardiovascular deaths in hospitalized patients with atrial fibrillation (54.1%) could be 
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viewed as being somewhat higher than the rates reported for the general population in the United 
States (30.8%) 32 and in France (27.5%)33. As such, atrial fibrillation may not simply reflect 
cardiovascular ageing and would differ from general population trends. 
 
CONCLUSION 
In a large cohort of unselected patients with atrial fibrillation, the majority of deaths was not 
related to a fatal ischemic stroke or a fatal hemorrhage. The three main causes of death were heart 
failure-related death, infections and cancer. Despite the high risk of stroke associated with atrial 
fibrillation, only 7% died from stroke. Optimization of management of any underlying heart 
disease and associated comorbidities should be a relevant therapeutic target to reduce total 
mortality in atrial fibrillation patients. 
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Figure legend. 
Figure 1. Cumulative mortality of patients with atrial fibrillation during the follow up.  
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Table 1: Characteristics of patients with atrial fibrillation alive or died at the end of the follow-up 
Variable 
Patients alive at 
the end of follow-
up 
7,668(86%) 
Patients who 
died during the 
follow-up 
1,294(14%) 
p 
Demographics    
Age (years), mean ± SD 70 ± 15 78 ± 10 <0.0001 
Women, n(%) 2,975(39) 492(38) 0.60 
Atrial fibrillation type and risk scores    
Permanent atrial fibrillation, n(%) 2,866(37) 629(49) <0.0001 
CHA2DS2-VASc score, mean ± SD 2.9 ± 1.7 3.9 ± 1.6 <0.0001 
HASBLED score, mean ± SD 1.5 ± 1.1 2.0 ± 1.1 <0.0001 
SAMe TT2R2, mean ± SD 1.46 ± 1.07 1.55 ± 1.16 0.007 
Cardiovascular risk factors    
Hypertension, n(%) 3156(41) 587(45) 0.005 
Diabetes mellitus, n(%) 1,134(15) 252(19) <0.0001 
Hyperlipidaemia, n(%) 1,513(20) 251(19) 0.08 
Current tobacco use, n(%) 930(12) 223(17) <0.0001 
Alcohol abuse, n(%) 255(3) 63(5) 0.006 
Cardiovascular Disease    
Heart failure, n(%) 3,958(52) 954(74) <0.0001 
Coronary artery disease, n(%) 2,189(29) 529(41) <0.0001 
Previous myocardial infarction, n(%) 991(13) 307(24) <0.0001 
Valvular heart disease, n(%) 1,659(22) 380(29) <0.0001 
NYHA III/IV (n=3,977), n(%) 902(27) 252(39) <0.0001 
LVEF (n=1,934), mean ± SD 48 ± 15 45 ± 17 0.01 
LVEF <40% (n=1934), n(%) 464(31) 163(38) <0.0001 
LBBB, n(%) 402(5) 119(9) <0.0001 
Prior stroke/TIA, n(%) 588(8) 150(12) <0.0001 
Comorbidities    
Renal failure, n(%) 552(7) 256(20) <0.0001 
eGFR (n=7,569), ml/min/1.73m2, mean ± SD 64 ± 24 56 ± 22 <0.0001 
Pulmonary disease, n(%) 742(10) 209(16) <0.0001 
Thyroid disorder, n(%) 569(7) 128(10) 0.003 
Previous major BARC bleeding, n(%) 360(5) 124(10) <0.0001 
Cancer, n(%) 130(2) 33(2) 0.04 
Therapy at discharge or during follow-up    
Oral anticoagulation (VKA) (n=8,120), n(%) 4,062(58) 575(51) <0.0001 
APT (Aspirin or Clopidogrel) (n=7,969), n(%) 2,261(33) 419(38) 0.002 
Dual APT (Aspirin and Clopidogrel) 
(n=7,905), n(%) 
467(7) 76(7) 0.97 
No prevention of thromboembolic risk 
(n=7,966), n(%) 
1,264(19) 262(24) 0.0002 
ACE inhibitor or ARB (n=8,671), n(%) 2,510(34) 539(44) <0.0001 
Beta-blocker (n=8,767), n(%) 3,427(46) 479(38) <0.0001 
Antiarrhythmic agent (n=8,362), n(%) 3,174(42) 519(41) 0.69 
Digoxin (n=8,871), n(%) 1,751(23) 408(32) <0.0001 
Diuretic (n=8,224), n(%) 2,664(38) 694(57) <0.0001 
Pacemaker or ICD, n(%) 1,266(17) 266(21) 0.0003 
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ACE: angiotensin converting enzyme inhibitor; APT: antiplatelet therapy; ARB: angiotensin receptor 
blocker; eGFR : estimated glomerular filtration rate using the MDRD equation; ICD: implantable 
cardioverter defibrillator. LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; SD: 
standard deviation;TIA: transient ischemic attack; VKA: vitamine K antagosnist;  
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Table 2: Causes of death in patients with atrial fibrillation 
 
Causes of death n % 
Total death 1,294 100.0 
 
  
Cardiovascular death 699 54.1 
Cardiac  419 32.4 
 Sudden cardiac death 42 3.3 
 Progressive heart failure 377 29.2 
 Vascular death 196 15.2 
 Ischemic stroke 87 6.7 
 Fatal haemorrhage 87 6.7 
 CNS fatal haemorrhage 53 4.1 
 non-CNS fatal haemorrhage 34 2.6 
 Pulmonary embolism 12 0.9 
 Acute aortic syndrome 10 0.8 
 Other cardiovascular death 82 6.4 
   
Non cardiovascular death 553 42.7 
Cancer 153 11.8 
Infection 227 17.6 
Renal failure 20 1.6 
Respiratory failure 41 3.2 
Trauma 35 2.7 
Cerebral trauma 18 1.4 
Other trauma 18 1.4 
Other non cardiovascular death 78 6.0 
   
Undetermined death 42 3.2 
 
CNS: central nervous system 
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Table 3: Effect of oral anticoagulation on incidences of different causes of death  
 
Causes of death 
no VKA 
n(%) 
3,483(100%) 
VKA  
n(%) 
4,637(100%) 
HR(95%CI) 
Non adjusted 
HR(95%CI) 
Adjusted 
Overall mortality 561(16.11) 575(12.40) 0.64(0.57-0.72) ‡ 0.62(0.54-0.71) ‡ 
 
    
Cardiovascular death 304(8.73) 307(6.60) 0.63(0.54-0.74) ‡ 0.60(0.49-0.72) ‡ 
Cardiac  180(5.17) 188(4.05) 0.65(0.53-0.78) ‡ 0.56(0.44-0.71) ‡ 
 Sudden cardiac death 19(0.55) 19(0.41) 0.62(0.33-1.17) 0.61(0.29-1.31) 
 Progressive heart failure 161(4.62) 169(3.64) 0.66(0.53-0.82) † 0.69(0.55-0.87) † 
 Vascular death 87(2.49) 90(1.94) 0.61(0.46-0.82) † 0.70(0.49-0.99)* 
 Ischemic stroke 36(1.03) 40(0.86) 0.70(0.44-1.09) 0.93(0.54-1.59) 
 Fatal haemorrhage 41(1.17) 40(0.86) 0.61(0.39-0.94)* 0.58(0.36-0.95)* 
 CNS fatal haemorrhage 22(0.63) 29(0.62) 0.80(0.46-1.40) 0.77(0.41-1.45) 
 non CNS fatal haemorrhage 19(0.54) 11(0.24) 0.37(0.18-0.78) † 0.36(0.16-0.81)† 
 Pulmonary embolism 3(0.09) 6(0.13) 0.84(0.80-0.88) ‡ 0.84(0.80-0.89) ‡ 
 Acute aortic syndrome 4(0.11) 4(0.09) 0.84(0.80-0.88) ‡ 0.84(0.80-0.89) ‡ 
 Other cardiovascular death 37(1.06) 29(0.62) 0.84(0.81-0.88) ‡ 
 
0.85(0.81-0.90) ‡ 
 
     
Non cardiovascular death 234(6.72) 253(5.46) 0.67(0.56-0.8) ‡ 0.60(0.49-0.74) ‡ 
Cancer 70(2.01) 71(1.53) 0.62(0.45-0.87) † 0.48(0.33-0.70) ‡ 
Infection 100(2.87) 94(2.03) 0.59(0.44-0.78) † 0.55(0.39-0.76) † 
Renal failure 6(0.17) 9(0.19) 0.93(0.33-2.61) 0.56(0.17-1.81) 
Respiratory failure 20(0.57) 17(0.37) 0.52(0.27-1.00)* 0.30(0.15-0.60) † 
Trauma 9(0.26) 24(0.52) 1.63(0.75-3.50) 3.45(1.39-8.33) † 
Cerebral trauma 7(0.20) 11(0.24) 0.97(0.38-2.50) 1.25(0.42-3.68) 
Other trauma 2(0.06) 13(0.28) 2.60(0.74-9.17) 12.35(2.51-62.5) † 
Other non cardiovascular death 31(0.89) 38(0.82) 0.76(0.47-1.22) 
 
0.84(0.80-0.88) ‡ 
 
     
Undetermined death 330(9.47) 346(7.46) 0.63(0.55-0.74) ‡ 
 
0.72(0.6-0.87) † 
 Adjustment for age, sex, characteristics of AF (permanent or non-permanent), comorbidities and treatments listed in 
table 1. VKA: vitamin K antagonist; HR: hazard ratio; CI: confidence interval; CNS: central nervous system;  
* p < 0.05; † p< 0.01; ‡ p < 0.0001 
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Table 4: Predictive factors for overall mortatily, cardiovascular death and non cardiovascular 
death  
APT: antipatelet therapy; CI: confidence interval; HR: hazard ratio; VKA: vitamin K antagonist.
 
HR(IC 95%)  
Non adjusted p 
HR(IC 95%) 
Adjusted p 
Overall mortality 
Age 1.06(1.05-1.07) <0.0001 1.06(1.05-1.06) <0.0001 
Women 1.01(0.91-1.07) 0.80 0.78(0.68-0.89) 0.0003 
Permanent atrial fibrillation 1.58(1.36-1.83) <0.0001 1.35(1.19-1.52) <0.0001 
Previous heart failure 2.16(1.90-2.44) <0.0001 1.78(1.53-2.06) <0.0001 
Previous myocardial infarction 1.69(1.49-1.92) <0.0001 1.43(1.18-1.74) 0.0002 
Prior stroke 
 
1.49(1.19-1.87) 0.0005 1.21(1.00-1.47) 0.05 
Renal failure 2.48(2.16-2.84) <0.0001 1.79(1.53-2.08) <0.0001 
Pulmonary disease 1.45(1.25-1.68) <0.0001 1.18(1.01-1.40) 0.04 
Previous bleeding 1.88(1.56-2.26) <0.0001 1.42(1.15-1.75) 0.001 
VKA 0.64(0.57-0.72) <0.0001 0.62(0.54-0.71) <0.0001 
APT 1.28(1.13-1.44) <0.0001 0.78(0.67-0.91) 0.001 
ß-blocker 0.75(0.66-0.84) <0.0001 0.78(0.68-0.88) 0.0001 
Cardiovascular death 
Age 1.06(1.06-1.07) <0.0001 1.06(1.05-1.07) <0.0001 
Women 1.03(0.89-1.20) 0.60 0.79(0.66-0.96) 0.01 
Permanent atrial fibrillation 1.58(1.36-1.83) <0.0001 1.43(1.21-1.70) <0.0001 
Previous heart failure 2.75(2.30-3.30) <0.0001 2.29(1.86-2.82) <0.0001 
Previous myocardial infarction 2.34(1.99-2.75) <0.0001 1.80(1.40-2.31) <0.0001 
Prior stroke 
 
1.49(1.19-1.87) 0.0005 1.33(1.03-1.71) 0.03 
Renal failure 2.95(2.47-3.52) <0.0001 1.93(1.58-2.35) <0.0001 
Previous bleeding 1.96(1.53-2.51) <0.0001 1.46(1.11-1.93) 0.01 
VKA 0.63(0.54-0.74) <0.0001 0.60(0.49-0.72) <0.0001 
APT 1.31(1.11-1.54) 0.001 0.73(0.60-0.89) 0.002 
Non cardiovascular death 
Age 1.05(1.04-1.06) <0.0001 1.05(1.04-1.06) <0.0001 
Women 0.90(0.75-1.07) 0.20 0.71(0.58-0.87) 0.0009 
Permanent atrial fibrillation 1.39(1.17-1.64) <0.0001 1.21(1.00-1.45) 0.05 
Alcohol abuse 1.53(1.09-2.16) 0.01 1.66(1.14-2.40) 0.01 
Previous heart failure 1.72(1.44-2.06) <0.0001 1.45(1.18-1.78) 0.0004 
Renal failure 2.00(1.59-2.50) <0.0001 1.50(1.17-1.91) 0.001 
Pulmonary disease 1.90(1.55-2.34) <0.0001 1.68(1.34-2.11) <0.0001 
Previous bleeding 1.74(1.30-2.34) 0.0002 1.40(1.02-1.94) 0.04 
VKA 0.67(0.56-0.80) <0.0001 0.60(0.49-0.74) <0.0001 
APT 1.23(1.02-1.49) 0.02 0.80(0.65-0.99) 0.04 
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Table 5: Predictive factors of heart failure death and sudden cardiac death  
 
 
ACE: angiotensin converting enzyme inhibitor; APT: antiplatelet therapy; ARB: angiotensin receptor 
blocker. CI: confidence interval; HR: hazard ratio; LBBB: left bundle branch block; VKA: vitamin K 
antagonist; 
 
 
 
HR(IC 95%) 
Non adjusted p 
HR(IC 95%)  
Adjusted p 
Heart failure death 
Age 1.06(1.05-1.07) <0.0001 1.05(1.04-1.06) <0.0001 
Women 0.93(0.75-0.15) 0.50 0.83(0.64-1.07) 0.14 
Permanent atrial fibrillation 1.43(1.17-1.75) 0.001 1.34(1.06-1.68) 0.01 
Diabetes mellitus 1.55(1.20-1.95) 0.0006 1.12(0.85-1.47) 0.42 
Current tobacco use 1.40(1.08-1.81) 0.009 1.05(0.78-1.42) 0.73 
Coronary artery disease 3.07(2.50-3.77) <0.0001 1.53(1.12-2.08) 0.01 
Previous heart failure 4.29(3.24-5.68) <0.0001 2.78(1.99-3.86) <0.0001 
Previous myocardial infarction 3.27(2.65-4.03) <0.0001 1.88(1.38-2.57) <0.0001 
LBBB 2.08(1.55-2.79) <0.0001 1.45(1.05-2.00) 0.02 
Renal failure 3.77(3.01-4.74) <0.0001 2.24(1.74-2.88) <0.0001 
VKA 0.66(0.53-0.82) 0.0002 0.69(0.55-0.87) 0.0002 
ACE inhibitor or ARB 1.49(1.21-1.83) <0.0001 0.98(0.77-1.24) 0.85 
ß-blocker 0.91(0.74-1.12) 0.36 0.78(0.62-0.98) 0.03 
Diuretic 2.60(2.10-3.23) <0.0001 1.41(1.09-1.82) 0.01 
Sudden cardiac death 
Age 1.04(1.01-1.07) 0.006 1.04(1.01-1.08) 0.02 
Women 0.75(0.39-1.44) 0.40 0.44(0.19-1.00) 0.05 
Previous heart failure 4.65(1.96-10.99) 0.0005 3.22(1.20-8.62) 0.02 
Previous myocardial infarction 2.43(1.26-4.67) 0.008 1.64(0.77-3.46) 0.20 
Renal failure 3.23(1.58-6.58) 0.001 2.45(1.15-5.21) 0.02 
VKA 0.62(0.33-1.17) 0.13 0.61(0.29-1.31) 0.21 
APT 2.16(1.12-4.15) 0.02 1.24(0.56-2.73) 0.60 
ACE inhibitor or ARB 1.34(0.07-2.58) 0.005 1.87(0.92-3.80) 0.08 
ß-blocker 
 
1.56(0.84-2.89) 0.16 1.53(0.75-3.11) 0.24 
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Table 6: Predictive factors of fatal ischemic stroke or fatal haemorrhage  
 
APT: antiplatelet therapy; HR: hazard ratio; CI: confidence interval; VKA: vitamin K antagonist;  
 
HR(IC 95%) 
Non adjusted p 
HR(IC 95%) 
Adjusted p 
Fatal ischemic stroke 
CHA2DS2VASc 1.59(1.42-1.79) <0.0001 1.27(1.08-1.49) 0.003 
Age 1.10(1.08-1.13) <0.0001 1.08(1.04-1.11) <0.0001 
Permanent atrial fibrillation 2.65(1.68-3.98) <0.0001 2.42(1.50-3.92) 0.0003 
Renal failure 1.77(0.98-3.18) 0.05 1.24(0.65-2.36) 0.52 
VKA 0.70(0.44-1.09) 0.11 0.93(0.54-1.59) 0.79 
APT 2.00(1.26-3.14) 0.003 1.33(0.78-2.27) 0.29 
Fatal haemorrhage      
CHA2DS2VASc 1.25(1.11-1.41) 0.0003 1.08(0.88-1.32) 0.48 
HASBLED 1.44(1.20-1.72) <0.0001 1.22(0.88-1.70) 0.23 
Age 1.05(1.03-1.07) <0.0001 1.05(1.03-1.08) <0.0001 
Renal failure 2.43(1.43-4.13) 0.001 1.71(0.88-3.32) 0.11 
VKA 0.61(0.39-0.94) 0.02 0.58(0.36-0.95) 0.03 
APT 1.19(0.75-1.87) 0.46 0.66(0.38-1.15) 0.14 
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Clinical significance 
• Cardiovascular events were the most common cause of death (54% of cases) in a large 
study of hospitalized patients with atrial fibrillation.  
• Fatal stroke or fatal bleeding each accounted for 7% of all deaths. 
• The strongest predictors of overall death were permanent atrial fibrillation, heart failure 
(whether with decreased or with preserved ejection fraction), previous bleeding and renal 
failure. 
• Oral anticoagulant use was independently associated with a lower risk of all-cause 
mortality, cardiovascular mortality, and non-cardiovascular mortality. 
 
 
